Award Winner at the Nordic Innovation Fair 2022

Epigenica is attended the Nordic Innovation Fair 2022 and became the Top Pitching case in its session.

Epigenica to attend the Nordic Innovation Fair 2022

Epigenica is chosen to attend the Nordic Innovation Fair on the 26th-27th of September, as one of the 30 most promising business opportunities.

Epigenica joins KI Innovation’s DRIVE incubator

Epigenica is happy to have joined the DRIVE Business Incubator at Karolinska Institutet Innovation. DRIVE is a dedicated life science incubator program which supports successful commercial development of businesses.

minute: A MINUTE-ChIP data analysis workflow

minute: A MINUTE-ChIP data analysis workflow Carmen Navarro, Marcel Martin, Simon Elsässer doi: https://doi.org/10.1101/2022.03.14.484318 Abstract Quantitative ChIP-seq methods are essential for accurately characterizing and comparing genome-wide DNA-protein interactions across samples. Procedures that enable such quantitative comparisons involve addition of spike-in chromatin or recombinant nucleosome material, or a multiplexed process using barcoding of chromatin fragments. ChIP-seq… Continue reading minute: A MINUTE-ChIP data analysis workflow

Epigenica granted €150,000 from the ERC for a 2nd time

Epigenica has been awarded a Proof-of-Concept grant of €150,000 to begin commercialization of a new platform technology. The ERC PoC hmqPro will focus on developing novel highly-multiplexed, quantitative biomarker profiling.

Epigenica receives grant from ALMI innovation

ALMI Innovation has provided seed funding for Epigenica to develop the company IP portfolio.

Epigenica receives grant from KI innovation

KI Innovation has provided seed funding for Epigenica to develop the company IP portfolio.

Epigenica granted €150,000 from the European Research Council

A Proof-of-Concept grant from the European Research Council (€150,000) marks the start of Epigenica and will allow Epigenica to further develop the platform and shorten our road to reach the market.

This website uses cookies. By continuing to use this site, you accept our use of cookies.